The inhibition of osteoclast differentiation/bone resorption is a well-known therapeutic strategy for controlling pathological and postmenopausal bone loss. Natural products that specifically inhibit osteoclastogenesis could therefore be developed as antiresorptive drugs for the treatment of metabolic bone disorders characterized by excessive osteoclastic bone resorption. We therefore examined the effects of Rubus coreanus extract (eeRc) on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced differentiation of bone marrow macrophages (BMMs) into osteoclasts and pit formation in vitro. Additionally, the in vivo effects of the eeRc were observed in mice with lipopolysaccharide (LPS)-induced bone erosion. In this study, we found that the ethanolic extract of Rubus coreanus fruits considerably suppressed the RANKL-induced differentiation of primary BMMs into osteoclasts and bone-resorbing activity of mature osteoclasts. Oral administration of eeRc attenuated LPS-induced bone loss in vivo, as demonstrated by the reversal of LPS-induced reduction in bone volume per tissue volume, bone mineral density, and trabecular number to some extent in eeRc-treated mice. In addition, eeRc slightly decreased the serum levels of C-terminal telopeptide fragments of type I collagen, the collagen-breakdown product generated by osteoclasts. Collectively, our results indicate that eeRc has the potential to inhibit bone loss by blocking osteoclast differentiation and could therefore be a promising natural product for the prevention and/or treatment of inflammatory bone loss.
Bone is constantly remodeled, and bone mass is tightly regulated by the balance between osteoclast-mediated bone resorption and osteoblast-induced bone formation [1] . In general, most adult skeletal diseases, such as osteoporosis and rheumatoid arthritis, are caused by an imbalance in bone remodeling characterized by excessive bone resorption relative to bone formation [2] .
Osteoporosis, the most frequent metabolic bone disease, may be caused by several factors, such as hormonal imbalance, chronic diseases, or medications [3] . Postmenopausal osteoporosis, which occurs in women because of estrogen deficiency, is the most common type of osteoporosis [4, 5] . Although hormone and antiresorptive therapies, such as bisphosphonates, selective tissue estrogenic activity regulators, and calcitonins, are currently approved for the treatment of osteoporosis [6, 7] , these treatments have specific side effects such as mastalgia, breast cancer, and endometrial hyperplasia [8, 9] . Recently, foods of plant origin, especially fruits, vegetables, and edible seaweeds, have drawn increased attention and are being extensively investigated for their beneficial effects on bone remodeling [10, 11] .
Lipopolysaccaride (LPS) leads to the intracellular induction of p38, JNK, and NFκB in macrophages and monocytes. When macrophages are exposed to stimuli such as LPS, IκB is phosphorylated by IκB kinase (IKK) and NF-κB is separated from the phosphorylated IκB [12, 13] . Therefore, activation of NF-κB leads to inflammatory responses, and promotes the differentiation and survival of osteoclasts [14, 15] . Therefore, LPS is an important mediator of pathological bone destruction associated with inflammation [16] .
Rubus coreanus (black raspberry or Bokbunja), a well-known health food in Korea, has been used as a folk medicine and functional food and exhibits several medicinal properties including antioxidant [17] , anti-inflammatory [18] , anticancer [19] , and antiobesity properties [20, 21] . Although a few studies have previously reported the anti-osteoclastic and/or bone protective effects of different R. coreanus products [22, 23] , those studies were primarily conducted using ovariectomy-induced osteoporosis models or osteoblast-like MC3T3-E1 cells.
As both mononuclear osteoclast progenitor cells and osteoclast-like
MNCs are TRAP-positive, the effects of eeRc treatment on MNC formation as well as total TRAP activity were examined. After 4 days of culture, TRAP-positive MNCs were generated in the positive control ( Figure 1A ; RANKL control). When eeRc was added to the cultures at the same time as RANKL, a dose-dependent inhibition of osteoclast-like MNC formation was observed, with complete inhibition at a dose of 50 μg/mL of eeRc ( Figure 1A and 1B). However, unlike MNC formation, TRAP activity was suppressed only by 200 μg/mL of eeRc and not by 50 μg/mL of the extract ( Figure 1B) . These results suggest that eeRc does not suppress the formation of TRAP-positive mononuclear preosteoclasts from progenitor cells but suppresses osteoclast-like MNC formation by inhibiting cell fusion. Further, an evaluation of the effect of eeRc on BMM viability showed that eeRc did not negatively affect the viability of BMMs at any of the tested concentrations (up to 200 μg/mL). This confirmed that the inhibitory effects of eeRc on osteoclast formation were not due to its cytotoxicity (Data not shown).
Osteoclast differentiation involves three general steps namely, rapid division and subsequent differentiation of monocyte/macrophage precursors into TRAP-positive mononuclear preosteoclasts, fusion of TRAP-positive mononuclear preosteoclasts to form nonfunctional osteoclast-like MNCs, and finally, osteoclast activation (maturation) [24] . To determine the stage of osteoclastogenesis targeted by eeRc, the extract was added to BMM cultures simultaneously with RANKL on day 0 or after 1, 2, or 3 days, as indicated in Figure 2C . Representative images of TRAP staining are shown in Figure 2A . The addition of eeRc on day 0 almost completely inhibited osteoclast-like MNC formation but not the formation of TRAP-positive mononuclear preosteoclasts. While treatment with eeRc on day 2 after the onset of differentiation (1 ~ 4 days) partially reduced the formation of TRAP-positive MNCs, treatment with eeRc on day 3 (2 ~ 4 days) failed to inhibit both osteoclast-like MNC formation and TRAP activity ( Figure 2B ). These results suggest that eeRc suppresses the fusion of mononuclear preosteoclasts but not their formation from progenitor cells.
During activation, differentiated multinuclear osteoclasts polarize on the bone surface, adhere to it, and secrete protons and protonactivated hydrolytic enzymes into the extracellular compartment to degrade the bone matrix [2] . BMMs were incubated on bone slices in an osteoclast-inducing medium for 3 days to generate osteoclastlike MNCs and then treated with eeRc (50 μg/mL) or vehicle for an additional 24 h. Treatment with eeRc caused a slight decrease in Figure 3A) . Measurement of the resorbed areas revealed approximately 63% inhibition of bone resorption at a dose of 50μg/mL of eeRc ( Figure 3B ). These results suggest that eeRc inhibits the bone-resorbing activity of mature osteoclasts to some extent.
Bone resorption, which is mediated by osteoclasts, can induce the loss of calcified bone tissue. As eeRc was observed to suppress RANKL-induced osteoclastogenesis as well as the bone-resorbing activity of mature osteoclasts in vitro, we investigated whether eeRc has bone protective effects in vivo, using a mouse model of LPSinduced bone loss. LPS administration to mice also resulted in trabecular bone loss from femurs ( Figure 4A ), which was reversed to some extent by co-injection of eeRc. In addition, eeRc caused a slight improvement in overall bone quality in the absence of LPS injection. In correlation with the μCT images, the LPS-induced reduction in bone volume per tissue volume (BV/TV), bone mineral density (BMD), trabecular number (Tb. N), trabecular thickness (Tb. Th), and trabecular separation (Tb. Sp) and increase in the number of TRAP-positive osteoclasts were also attenuated in eeRctreated mice ( Figure 4B and Figure 4C ).
The serum CTX level, which was elevated following LPS injection (31.71±1.05 versus 28.35±0.86 ng/mL in LPS versus sham group, p<0.05), was significantly inhibited by treatment with 50 mg/kg of eeRC ( Figure 4D) . Moreover, the serum CTX levels were lower in eeRc group mice than in sham group mice. Collectively, these results suggest that the protective effects of eeRc against LPSinduced bone loss are mainly owing to the inhibition of osteoclastic bone resorption. 
Rubus coreanus extracts inhibit LPS-induced bone loss

Experimental
General reagents: α-Modified minimal essential medium (α-MEM), fetal bovine serum (FBS), and penicillin-streptomycin were purchased from Gibco-BRL (Grand Island, NY, USA). Recombinant macrophage colony-stimulating factor (M-CSF) and RANKL were purchased from R&D Systems (Minneapolis, MN, USA). Red blood cell (RBC) lysis buffer and a tartrate-resistant acid phosphatase (TRAP) staining kit (Acid Phosphatase, Leukocyte (TRAP) kit [catalog no. 387-A]) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The CellTiter 96® AQueous One Solution Cell Proliferation Assay kit was purchased from Promega (Madison, WI, USA). All other chemical and reagents used were of analytical grade.
Preparation of the ethanolic extract of R. coreanus fruits (eeRc):
Dried R. coreanus fruits were obtained from a medical shop in Yak-Jun Street (Daegu, Korea) and extracted as described previously [26] . Briefly, dried R. coreanus fruits were ground and extracted with 100% ethanol (1:10 (w/v), 45 °C) for 24 h. After extraction, the solution was filtered through a Whatman® No. 4 filter paper (Whatman, Buckinghamshire, UK), and the filtrate was lyophilized.
The freeze-dried eeRc powder was dissolved in dimethyl sulfoxide and diluted with phosphate-buffered saline (PBS) for in vitro and in vivo assays. A voucher specimen (2016-Rc) was deposited in the Food Enzyme Biotechnology laboratory of Kyungpook National University (Daegu, Korea).
Cell culture and osteoclast differentiation: Osteoclasts were cultured as described previously [27] . Briefly, bone marrow cells were obtained from the tibias and femurs of 7-week-old male C57BL/6 mice (Samtaco Korea, Osan, Korea). After RBC lysis, the cells were suspended in α-MEM containing 10% FBS and cultured in 100-mm dishes in the presence of 1 ng/mL M-CSF for 24 h. The non-adherent cells were then plated and cultured in the presence of 10 ng/mL M-CSF for 3 days. After 3 days, the attached cells were used as BMMs. For osteoclast differentiation, the BMMs were seeded in 96-well plates (1.0 x 104 cells/well) and cultured in α-MEM complete medium supplemented with M-CSF (10 ng/mL) and RANKL (20 ng/mL) for 4 days in the absence or presence of eeRc, which was added simultaneously with M-CSF and RANKL on day 0 or after 1, 2, or 3 days. Primary mouse bone marrow stromal cells (BMSCs) were isolated and cultured as described previously [28] .
TRAP assay: TRAP staining was performed as described previously [11] . Briefly, after 4 days of culture (as described in section 2.3), the cells were fixed in 4% paraformaldehyde for 20 min and stained for TRAP with naphthol AS-MX phosphate and tartrate solution. TRAP-positive multinucleated cells (MNCs) containing more than three nuclei were counted as osteoclasts. The TRAP activity was measured by adding 100 μL of substrate solution (3.7 mM of p-nitrophenyl phosphate and 10 mM of sodium tartrate in 50 mM citrate buffer, pH 4.6) to the fixed cells, incubating at 37 °C for 10 min, and then adding an equal volume of 0.1 N NaOH solution. The absorbance at 405 nm was measured using a VersaMax™ microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Resorption pit assay:
The bone resorption assay was performed as described previously [29] . Briefly, BMMs were placed on bone slices (IDS Nordic, Herlev, Denmark) and cultured with M-CSF (10 ng/mL) and RANKL (20 ng/mL) to generate osteoclast-like MNCs. The generated osteoclasts were then cultured in the presence of M-CSF and RANKL with or without eeRc treatment (50 μg/mL) for 24 h. The resorption pits were visualized by hematoxylin staining, and the pit area was measured using ImageJ software (version: 1.50i; National Institutes of Health, Bethesda, MD, USA).
Histomorphometric analysis of femurs from LPS-induced bone loss model mice:
All animal procedures were performed in accordance with protocols approved by the Ethics Committee of Animal Care and the Committee of Kyungpook National University. C57BL/6 male mice (n = 24), aged 8 weeks, were obtained from Samtaco Korea (Osan, Korea). The mice were randomly divided into the following four groups (n = 6 mice per group): sham or control (treated with PBS alone), LPS (treated with LPS alone), eeRc (treated with eeRc alone) and LPS + eeRc (treated with both LPS and eeRc) groups. LPS (5 mg/kg) was intraperitoneally injected on days 2 and 6. PBS or eeRc (50 mg/kg) was administered orally 1 day before the first LPS injection (5 mg/kg), and for 8 days thereafter. At the end of the treatment, all mice were sacrificed in a CO2 chamber, and both femurs of each mouse were excised and fixed in 4% paraformaldehyde for 16 h. The fixed femurs were then scanned using a high-resolution microcomputed tomography system (μCT, SkyScan 1272, Bruker, Kontich, Belgium) with a source voltage of 60 kV, current of 166 μA, and resolution of 14 μm. The histomorphometric parameters were calculated using the CT-analyser (CTan) software (Bruker, Kontich, Belgium). For histological analysis, the fixed femurs were decalcified and embedded in paraffin, and histological sections (7 μm thickness) were stained for TRAP.
Determination of bone metabolic marker levels:
The effects of various treatments on bone resorption were evaluated via detection of the levels of C-terminal telopeptide fragments of type I collagen (CTX), the collagen-breakdown product generated by osteoclasts [25] , using a RatLaps™ enzyme-linked immunosorbent assay (ELISA) kit (Nordic Bioscience Diagnostics, Herlev, Denmark), according to the manufacturer's instructions.
Statistical analysis:
Data are expressed as the mean ± standard deviation (SD). Student's t-test was used for the comparison of parameters between two groups, and analysis of variance followed by Tukey's post-hoc test was used for multi-group comparisons. Values of p < 0.05 were considered statistically significant.
